Sometimes you need to cut your startup’s school ties
It's possible to build a startup with a founder who wants to stay in academia, but it’s not without its challenges.
Learn what it takes to turn a lab idea into a real business
Turning a great idea into a viable startup takes patience, perseverance and more than a little luck. But when an idea originates in a lab — whether it’s AI, biotech, robotics or another deep tech
The 5 most interesting startups in this IndieBio cohort
The startups in this IndieBio cohort are health-forward, with nine focusing on the health of the planet and four tackling challenges in human health.
3 climate tech VCs share how they find, vet and support carbon-slashing startups
Three investors active in the space joined me on stage at TC Sessions: Climate 2022 this week in Berkeley to share why they’re in it for the long haul.
A decade after the bubble burst, 5 climate tech investors explain why they’re all in
What’s a climate tech founder to do when faced with tight timelines and tighter funding rounds? We asked some of the leading investors in the space to share their perspectives.
Joywell Foods raises $25M to bring sweet proteins to market
Joywell uses a proprietary microbial fermentation process to produce sweet proteins that are nearly identical to those found in exotic fruits and berries.
College students and recent grads: Grab a $45 pass to TC Sessions: Climate 2022
The future of humanity itself is at stake, and that’s the driving thesis behind TC Sessions: Climate 2022 (presented by Extreme Tech Challenge), which takes place in person on June 14 at UC Berkeley
SOSV and JetBlue Technology Ventures talk VC climate tech and ESG at TC Sessions: Climate 2022
Investment in climate tech is heating up almost as fast as climate change itself. In 2021, climate tech startups received $40+ billion across more than 600 deals. That’s more than double the capital
Meet the 13 startups in IndieBio’s SF cohort, and discover what about each swayed investors
It’s been a big two years for biotech investors. But if you ask Po Bronson, a partner at SOSV’s IndieBio, this trend was probably a long time coming. “Often, the implication is that everything
Here’s all 10 companies from IndieBio’s latest New York cohort
Most big accelerators tend to dedicate some of their resources to dauntingly hard science problems and the companies taking them on… but for SOSV’s IndieBio, it’s the primary focus.
SOSV’s burgeoning climate portfolio is worth nearly $6 billion as planetary health bets pay off
The burgeoning climate-focused portfolio from early-stage investor SOSV Investments has managed to raise nearly $2 billion in follow-on financing since the startup companies graduated from the investm
From improving cancer treatments to saving the bees, these are the companies in IndieBio’s latest class
Ultra-precise cancer therapies! Human-like hair grown from plants! A way to potentially save the bees! The spectrum of companies coming out of IndieBio has always been pretty wild, and its latest batc
Early-stage investor Mayfield shows how to scale up your biotech startup at TC Early Stage in April
Founders in the earliest stages of startup life face a hefty learning curve. Just some of the core competencies you need to lock down include how to raise VC funding, recruiting the right people, find
Next-gen skincare, silk without spiders and pollution for lunch: Meet the biotech startups pitching at IndieBio’s Demo Day
Biotech can often, and sometimes literally, fly over our heads. However, the pandemic has shown an increased need for investment and focus on solutions that work on human and planetary health. For Ind
Synthetic biology startups are giving investors an appetite
There’s a growing wave of commercial activity from companies that are creating products using new biological engineering technologies. Perhaps the most public (and tastiest) example of the promi
Leaving the $3.2 billion portfolio he helped build at IndieBio, Arvind Gupta joins Mayfield to create the Genesis Consortium
Arvind Gupta, the founder and head of IndieBio, is leaving the accelerator whose portfolio he helped build into a $3.2 billion life sciences powerhouse, to join the venture capital fund Mayfield. The
Frontier technologies are moving closer to the center of venture investment
As the technologies that were once considered science fiction become the purview of science, the venture capital firms that were once investing at the industry’s fringes are now finding themselv
Biotech researchers venture into the wild to start their own business
Much of Silicon Valley mythology is centered on the founder-as-hero narrative. But historically, scientific founders leading the charge for bio companies have been far less common.
Watch biotech startups pitch at IndieBio’s demo day today
IndieBio, the biotech startup accelerator that's produced heaps of notable companies (including several that have graced the Startup Battlefield), is holding its twice-annual demo day today. An even d
Watch IndieBio’s Demo Day today
Today, April 17th at 2:00 PT, TechCrunch is bringing you IndieBio‘s Demo Day. IndieBio is a four-month accelerator focusing on biotech companies. Early-stage companies are given mentorship, 24/7